The Calcineurin Inhibitor market is estimated to be valued at US$ 10.07 Bn or Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The calcineurin inhibitor market consists of cyclosporine and tacrolimus drugs which are used to prevent rejection in organ transplant recipients. These drugs suppress the immune system by inhibiting T-cell activation. Calcineurin inhibitors are commonly used post kidney, liver and heart transplants. They are usually taken lifelong by transplant patients to avoid organ rejection.

Market Dynamics:
The calcineurin inhibitor market is expected to grow at a rapid pace owing to rising kidney transplant procedures worldwide. According to the Global Observatory on Donation and Transplantation, around 133,508 solid organ transplants were carried out globally in 2018, including 95,655 kidney transplants. Increasing cases of end stage renal disease (ESRD) and growing awareness about organ donation is fuelling the demand for kidney transplants. As calcineurin inhibitors are commonly prescribed post-kidney transplant, rising number of procedures directly contribute to market growth. Additionally, shortage of organs for transplantation is encouraging the use of expanded criteria donor kidneys which have higher risk of rejection and require long-term use of calcineurin inhibitors. Long-term medications adherence and follow ups post transplantation further support market gains over the forecast period.

SWOT Analysis

Strength: The calcineurin inhibitor market has a strong presence globally. The drugs are effective in treating autoimmune diseases and for immunosuppression. The market is well established with presence of many major players.

Weakness: Long term usage of calcineurin inhibitors can cause side effects like kidney damage, high blood pressure etc. These drugs also have a narrow therapeutic index requiring constant monitoring.

Opportunity: Increase in autoimmune disorders and post organ transplant patient pool worldwide presents lucrative growth opportunities. Emergence of combination therapies can further boost the market size.

Threats: Patent expiries of major drugs allows entry of generic versions intensifying competition. Stringent regulatory norms for approval of new drugs can impact overall market growth.

Key Takeaways:

The Global Calcineurin Inhibitor Market Demand is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of autoimmune disorders and rise in organ transplant procedures worldwide. As per estimates, the market was valued at US$ 10.07 Bn in 2023 and is projected to reach US$ 21.45 Bn by 2030.

Regional analysis

North America dominated the global calcineurin inhibitor market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to growing autoimmune disease burden, availability of advanced healthcare facilities and presence of prominent market players in the region. Meanwhile, Asia Pacific is expected to exhibit the fastest CAGR driven by expansion of healthcare infrastructure, rise in medical tourism and increased government focus on quality care in major country markets such as India and China.

Key players

Key players operating in the calcineurin inhibitor market are Novartis AG, Astellas Pharma Inc., LEO Pharma A/S, Allergan, Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Roche Holding AG, Bristol Myers Squibb Company, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Mylan N.V. These companies adopt strategies such as mergers, acquisitions and new product launches to strengthen their market position.

Read More:

https://insightskies12.blogspot.com/2023/11/biologics-is-fastest-growing-segment.html